Table 4.
Published information on the impact of licensed vaccines against SARS-CoV-2 infection and associated disease in protecting against infection and disease from different viral variants.
| vaccine | efficacy against transmission from phase 3 trials |
effective or not against infection of different variants |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| after 1st dose | after 2nd dose | variants of concern (VOC) |
variants of interest (VOI) |
|||||||
| B.1.1.7 (Alpha) | B.1.351 (Beta) | P.1 (Gamma) | B.1.617 (Delta) | B.1.525 (Eta) | B.1.526 (Iota) | B.1.617 (Kappa) | C.37 (Lambda) | |||
| Oxford-Astra Zeneca | 67% [117] | 50% [117] | yes (70.4% [147]–74.5% [127]) | no (10.4%) [148] | unknown | yes (67%) [127] | unknown | yes | unknown | |
| Moderna | ≥61% (estimate) [149] | unknown | unknown | remains to be determined [150] | unknown | yes [121] | unknown | yes [121] | unknown | |
| Pfizer-BioNTech | unknown | yes (89.5%) [151,152] | yes (75%) [152,153] | unknown | yes (64% [154]–88% [127]) | unknown | yes [153] | unknown | ||
| Sinopharm | unknown | yes [155] | yes [156] | unknown | ||||||
| Sinovac | unknown | yes [157] | yes [157] | no [100] | unknown | |||||
| Sputnik V (Gamaleya) | unknown | unknown | yes (90%) [158] | unknown | ||||||
| Novaxvax | unknown | yes (86.3%) [138] | yes (49.4–60%) [139,159] | unknown | ||||||
| Johnson & Johnson | 74% [140] | — | unknown | yes [160] | unknown | |||||
| CanSino | unknown | unknown | ||||||||